Veracyte, Inc., a South San Francisco-based firm that focuses on molecular cytology, has completed a $28-million Series C financing round to support the expansion and rollout of the company’s first product, Afirma® Thyroid FNA Analysis, a thyroid nodule test, which is evidently the only molecular test clinically validated to meet the criteria of National Comprehensive Cancer Network guidelines for safely monitoring thyroid nodules in lieu of invasive diagnostic surgery.

“We are pleased to have the support of GE Ventures, as well as of our current investors,” said Co-Founder and CEO Bonnie Anderson. “This funding will help Veracyte expand availability of our Afirma Thyroid FNA Analysis to help more patients with inconclusive thyroid nodule fine needle aspiration (FNA) biopsy results potentially avoid unnecessary thyroid surgery.” The financing included new investor GE Ventures, as well as existing investors Domain Associates, Kleiner Perkins Caufield & Byers, TPG Biotech, and Versant Ventures. See Veracyte, Inc. News Release, June 27, 2013.